Donepezil 10 mg/day vs placebo
Cognitive function · people with severe Alzheimer's disease
2 findings from 1 review
- no estimate extracted4 studies · 1102 participantsModerate
- no estimate extracted5 studies · 1348 participantsModerate
Findings
What do systematic reviews say?
3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only
No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%
Donepezil 10 mg/day vs placebo
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.78 [1.31, 2.43]3 studies · 755 participantsModerate
Donepezil 10 mg/day vs placebo
Change in capacity for activities of daily living · people with severe Alzheimer's disease
1 finding from 1 review
- no estimate extracted3 studies · 733 participantsModerate
Donepezil 10 mg/day vs placebo
Secondary outcome: acceptability of treatment · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.32 [1.02, 1.71]5 studies · 1396 participantsModerate
Donepezil 10 mg/day vs placebo
Risk for at least one adverse event per patient · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.59 [1.23, 2.05]5 studies · 1396 participantsModerate
Donepezil 10 mg/day vs placebo
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted3 studies · 733 participantsModerate
Donepezil 10 mg/day vs placebo
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.92 [1.54, 2.39]6 studies · 1674 participantsModerate
Donepezil 10 mg/day vs placebo
Behavioural symptoms (change from baseline at 26 weeks measured using the NPI) · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted4 studies · 1035 participantsModerate
Donepezil 10 mg/day vs placebo
Acceptability · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.25 [1.05, 1.5]12 studies · 2846 participantsModerate
Donepezil 10 mg/day vs placebo
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
- OR 1.59 [1.31, 1.95]10 studies · 2500 participantsModerate
Donepezil 10 mg/day vs placebo
Quality of life of participants (change from baseline at 26 weeks) · people with Alzheimer's disease
1 finding from 1 review
- no estimate extracted2 studies · 815 participantsModerate
Risedronate 5 mg/day vs placebo
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Risedronate 5 mg/day vs placebo
Wrist fractures · pPostmenopausal women at higher risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.64 [0.33, 1.24]Studies not reportedVery low
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.98 [0.9, 1.07]Studies not reportedHigh
Risedronate 5 mg/day vs placebo
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 1 [0.94, 1.07]Studies not reportedModerate
Risedronate 5 mg/day vs placebo
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.54 [0.22, 1.35]Studies not reportedVery low
Risedronate 5 mg/day vs placebo
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Risedronate 5 mg/day vs placebo
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.48 [0.03, 7.5]Studies not reportedLow
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.67 [0.38, 1.18]Studies not reportedLow
Risedronate 5 mg/day vs placebo
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.74 [0.42, 1.3]Studies not reportedVery low